AstraZeneca’s Tagrisso with the addition of pemetrexed and platinum-based chemotherapy has been approved in the European Union for the first-line treatment of adult patients with advanced epidermal growth factor receptor-mutated, or EGFRm, non-small cell lung cancer, or NSCLC, whose tumors have exon 19 deletions or exon 21 mutations, the company announced.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca price target raised to 11,700 GBp from 11,300 GBp at Jefferies
- AstraZeneca’s MAA for sipavibart accepted by EMA for COVID-19 prevention
- AstraZeneca’s Imfinzi, Lynparza recommended for approval in EU by CHMP
- AstraZeneca says Tagrisso with addition of chemo approved in China for NSCLC
- UK Stocks: AstraZeneca’s (AZN) Imfinzi Disappoints in Advanced Lung Cancer Trial